The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Emcitate tiratricol New molecular entityPriority review | Rare Thyroid | 🇺🇸 US 2026-09-28 | Order → | |
| Atebrioz zilurgisertib fumarate New molecular entityPriority review | Mirum | 🇺🇸 US 2026-09-25 | Order → | |
| Cavoley pegfilgrastim BiosimilarAdditional monitoring | CuraTeQ Biologics s.r.o | Neutropenia | 🇪🇺 EU 2026-09-25 | Order → |
| Degevma denosumab-adet Biosimilar | Teva Pharmaceuticals, Inc. | 🇺🇸 US 2026-09-25 | Order → | |
| Juvmo tavapadon New molecular entity | Abbvie | 🇺🇸 US 2026-09-25 | Order → | |
| Lamlique lamotrigine hemifumarate New active ingredient | Azurity | 🇺🇸 US 2026-09-25 | Order → | |
| Zueino diclofenac sodium New formulation or manufacturer | Adventapharma | 🇺🇸 US 2026-09-25 | Order → | |
| Lyrfigtu lirafugratinib hydrochloride New molecular entityPriority review | Elevar | 🇺🇸 US 2026-09-23 | Order → | |
| Onswik insulin efsitora alfa-gobe Biosimilar | Eli Lilly And Co | 🇺🇸 US 2026-09-23 | Order → | |
| Carbon Dioxide, Usp carbon dioxide, usp | Agl Welding Supply Co Inc Dba Agl Gas Technologies | 🇺🇸 US 2026-09-22 | Order → | |
| Nezglyal leriglitazone OrphanExceptional circumstancesAdditional monitoring | Minoryx Therapeutics S.L. | Adrenoleukodystrophy | 🇪🇺 EU 2026-09-21 | Order → |
| Icotyde icotrokinra hydrochloride Additional monitoring | Janssen-Cilag International | Psoriasis | 🇪🇺 EU 2026-09-18 | Order → |
| Ruxolitinib Viatris ruxolitinib hemifumarate Generic | Viatris Limited | Primary Myelofibrosis; Polycythemia Vera; Graft vs Host Disease | 🇪🇺 EU 2026-09-18 | Order → |
| Susvimo ranibizumab Additional monitoring | Roche Registration GmbH | Wet Macular Degeneration | 🇪🇺 EU 2026-09-18 | Order → |
| Tafamidis Accord tafamidis Generic | Accord Healthcare S.L.U. | Amyloidosis, Familial; Cardiomyopathies | 🇪🇺 EU 2026-09-18 | Order → |
| Zokovea ensitrelvir Additional monitoring | Shionogi B.V. | COVID-19 virus infection | 🇪🇺 EU 2026-09-18 | Order → |
| Bexlutry lutetium lu-177 dotatate New formulation or manufacturer | Curium | 🇺🇸 US 2026-09-14 | Order → | |
| Isembyld apitegromab-mstn New biologicPriority review | Scholar Rock Inc | 🇺🇸 US 2026-09-11 | Order → | |
| Pixclara floretyrosine f-18 New molecular entityPriority review | Telix | 🇺🇸 US 2026-09-11 | Order → | |
| Etcamah camizestrant New molecular entity | Astrazeneca | 🇺🇸 US 2026-09-04 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.